Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal.
Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Portugal; PhD Trials, Rua das Murtas, n°1B, 1° - 1700-309, Lisboa, Portugal.
Toxicol Appl Pharmacol. 2018 Mar 1;342:14-21. doi: 10.1016/j.taap.2018.01.018. Epub 2018 Feb 4.
The safety profile of the ingredients used in topical dosage forms and its evaluation is an issue of utmost importance. A suitable equilibrium between safety and efficacy is crucial before promoting a dermatological product. The aim of this work was to assess the safety and biological effects of starch-based vehicles (St-BV) used in such products. The hazard, exposure and dose-response assessment were used to characterize the risk of each ingredient. The EpiSkin™ assay and human repeat insult patch tests were performed to compare the theoretical safety assessment to in vitro and in vivo data. The efficacy of the St-BV was studied using biophysical measurements in human volunteers during 28 days, showing that all ingredients and their combinations were safe for the consumer. Tissue viability determined using the EpiSkin™ testing reached values between 84.0 ± 5.0% and 98.0 ± 8.6% after application of St-BV, which were considered as non-irritant to the skin. These observations were confirmed by the in vivo studies where the St-BV did not induce any sensitization on the volunteers, being safe for human use. Moreover, St-BV increased skin hydration and microcirculation, emerging as an attractive alternative to chemical raw materials.
用于局部剂型的成分的安全性概况及其评估是至关重要的问题。在推广一种皮肤科产品之前,安全性和疗效之间需要达到适当的平衡。本工作旨在评估此类产品中使用的基于淀粉的载体(St-BV)的安全性和生物学效应。危害、暴露和剂量反应评估用于表征每种成分的风险。使用 EpiSkin™测定和人体重复斑贴试验将理论安全性评估与体外和体内数据进行比较。St-BV 的功效通过在 28 天内对人类志愿者进行生物物理测量进行研究,结果表明所有成分及其组合对消费者都是安全的。使用 EpiSkin™测试确定的组织活力在应用 St-BV 后达到 84.0±5.0%和 98.0±8.6%之间,被认为对皮肤无刺激性。这些观察结果通过体内研究得到证实,St-BV 未在志愿者中引起任何致敏作用,对人体安全。此外,St-BV 增加了皮肤的水合作用和微循环,作为化学原料的有吸引力的替代品出现。